Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
AKESO New Drug Marketing Application Approved by NMPA
Recommend 7 Positive 10 Negative 2 |
||||
|
||||
|
AKESO (09926.HK) announced that 奇佑康 (gumokimab, AK111) has received approval from the National Medical Products Administration of the People’s Republic of China (NMPA) for the treatment of moderate-to-severe plaque psoriasis. The approval of gumokimab for the treatment of moderate-to-severe plaque psoriasis is based on one pivotal Phase III clinical study (AK111-301) and three supportive studies. Currently, Phase III clinical trials for the registration of gumokimab for the treatment of moderate-to-severe plaque psoriasis and ankylosing spondylitis have met all efficacy endpoints. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
